Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2026)

Protagonist Therapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $7.4 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $7.4 million, down 24.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (down 24.05% YoY), and the FY2025 annual result was $8.0 million, down 22.36% from the prior year.
• Operating Leases came in at $7.4 million for Q1 2026 at Protagonist Therapeutics, down from $8.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $11.0 million in Q2 2024 to a low of $462000.0 in Q1 2023.
• The 5-year median for Operating Leases is $8.0 million (2025), against an average of $6.5 million.
• Across the five-year window, Operating Leases sank 84.91% in 2023 and declined 17.0% in 2025, its largest moves.
• Protagonist Therapeutics' Operating Leases stood at $1.1 million in 2022, then slumped by 59.51% to $462000.0 in 2023, then surged by 2141.56% to $10.4 million in 2024, then declined by 22.36% to $8.0 million in 2025, then slipped by 7.5% to $7.4 million in 2026.
• The last three Operating Leases figures came in at $7.4 million (Q1 2026), $8.0 million (Q4 2025), and $8.5 million (Q3 2025), per Business Quant data.